Male Urogenital Diseases and Microbiota

Öz

Human microbiota is a community of bacteria, fungi, viruses, and protozoa living in the human body outside the human cell. Microbiota can live anywhere in the body in accordance with their reproductive traits, the most suitable medium is the gastrointestinal system. Bowel microbiota has a special role in the development and progression of urinary system diseases. This microbiota is not static in human, responds to environmental factors and develops. It affects both oral food and medicines. Dietary and lifestyle differences among cultures lead to rapid and reproducible changes in the human gut. Similarly, oral and parenteral antibiotics have signifi cant effects on the microbial ecosystem in the human gastrointestinal tract. In recent years, intestinal microbiota has affected the composition of urine, which is thought to increase the incidence of stone formation. Oxalobacter formigenes is a gram (-) bacterium that breaks down in the intestine. Clinical fi ndings indicate that there is a direct relationship between hyperoxaluria and oxalate stone formation in the absence of this microorganism. It has been shown that orally administration of probiotic formulation of oxidizing microorganisms in humans and animals causes a temporary decrease in the amount of urinary oxalate. Clinical fi ndings indicate that there is a direct relationship between hyperoxaluria and oxalate stone formation in the absence of this microorganism. Lactobacillus, bifi dobacterium and enterococci are the most commonly have been used in this formulation. The circumcision described as removal of the preputial tissue of the penis may alter genital bacterial communities. Studies have shown that male circumcision reduces HIV, HSV type 2 and HPV infections. It also reduces trichomoniasis and bacterial vaginosis risk in partners of circumcised men. Probiotics prevent the multiplication of pathogenic microorganisms by providing intestinal and vaginal fl ora stabilization and probiotics shape the immune system, regulate intestinal endothelial cell, increase the bioavailability of minerals and vitamins and modify bowel movements. As a result it is now known that the impaired regulation of intestinal microbiota may play a role in the development of cancer, allergic conditions, metabolic and infl ammatory bowel diseases.

Anahtar Kelimeler

• Microbiota,Urogenital Diseases,Probiotics

Erkek Ürogenital Hastalıkları ve Mikrobiyota

Öz

İnsan mikrobiyotası, insan vücudunda yaşayan ve insan hücresi dışındaki bakteri, mantar, virüs ve protozoa ailesinden oluşan bir topluluktur. Mikrobiyotalar vücutta kendi üreme özelliklerine uygun her yerde yaşayabilirler, en uygun ortam ise gastrointestinal sistemdir. Fakat cilt, üst solunum sistemi ve ürogenital sistemde de bulunurlar. Üriner sistem hastalıkların gelişmesinde ve progresyonunda özellikle barsak mikrobiyotasının özel bir rolü vardır. Bu Mikrobiyota insanda statik değildir, çevresel faktörlere karşı cevap oluşturur ve gelişir. Bunu hem oral alınan yiyecekler hem de ilaçlar etkiler. Kültürler arasındaki diyet ve yaşam stili farklılıkları insan barsağında hızlı ve tekrar üretilebilir değişikliklere yol açar. Benzer şekilde hem oral hem parenteral alınan antibiyotiklerin insan gastrointestinal sisteminde mikrobial ekosistem üzerinde anlamlı etkileri vardır. Son yıllarda intestinal mikrobiyotanın idrarın kompozisyonunu etkilediği bunun da taş oluşumu insidansını arttırdığı düşünülmektedir. Oxalobacter formigenes oxalatı barsakta parçalayan gram (-) bir bakteridir. Bu mikroorganizmanın yokluğunda hiperoxalüri ve oxalat taşı oluşumu arasında direkt ilişki olduğunu klinik bulgular göstermektedir. Oxalatı parçalyan mikroorganizmalrın probiyotik formülasyonunda insan ve hayvanlarında oral olarak verilmesinin geçici olarak idrar oxalat miktarında azalmaya neden olduğu gösterilmiştir. Bu formülasyonda Lactobasillus, bifi dobakterium ve enterokoklar en çok kullanılmıştır. Peniste preputial dokunun çıkartılması olarak tanımlanan sünnet genital bakteriyel toplulukları değiştirebilir. Yapılan çalışmalar erkek sünnetinin HIV, HSV tip 2 ve HPV enfeksiyonlarını azalttığı gösterilmiştir. Ayrıca sünnetli erkeklerin bayan partnerlerinde de trichomoniasis ve bakteriyel vajinosis riskinin azaldığı görülmüştür. Probiyotikler intestinal ve vajen fl orasının dengesini sağlayarak patojen mikroorganizmaların çoğalmasını engeller, immün sistemi şekillendirir, barsak endotel hücresini düzenler, mineral ve vitaminlerin biyoyararlanımını artırır ve barsak haraketlerini modifi ye eder. Sonuç olarak İntestinal mikrobiyotanın kötü regülasyonunun kanser, alerjik durumlar, metabolik ve infl amatuvar barsak hastalıklarının gelişiminde rolü olabileceği artık bilinmektedir.

Anahtar Kelimeler

• Mikrobiyota,Ürogenital Hastalıklar,Probiotikler

Kaynakça

1. 1. Khanna S, Tosh PK. A clinician's primer on the role of the microbiome in human health and disease. Mayo Clin Proc. 2014;89(1):107-14.
2. 2. Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC; NISC Comparative Sequencing Program, Bouffard GG, Blakesley RW, Murray PR, Green ED, Turner ML, Segre JA. Topographical and temporal diversity of the human skin microbiome. Science. 2009; 29;324(5931):1190-2.
3. 3. Jiang J, Knight J, Easter LH, Neiberg R, Holmes RP, Assimos DG. mpact of dietary calcium and oxalate, and Oxalobacter formigenes colonization on urinary oxalate excretion. J Urol. 2011;186(1):135- 9.
4. 4. Borghi L, Nouvenne A, Meschi T. Probiotics and dietary manipulations in calcium oxalate nephrolithiasis: two sides of the same coin? Kidney Int. 2010;78(11):1063-5.
5. 5. Whiteside SA, Razvi H, Dave S, Reid G, Burton JP. The microbiome of the urinary tract--a role beyond infection. Nat Rev Urol. 2015;12(2):81-90.
6. 6. Arends, M. J. Pathways of colorectal carcinogenesis. Appl. Immunohistochem. Mol. Morphol.2013;21:97-102.
7. 7. Yang, T., Owen, J. L., Lightfoot, Y. L., Kladde, M. P. & Mohamadzadeh, M. Microbiota impact on the epigenetic regulation of colorectal cancer. Trends Mol. Med. 2013;19:714–725.
8. 8. Frank DN, Zhu W, Sartor RB, Li E. Investigating the biological and clinical signifi cance of human dysbioses. Trends Microbiol. 2011;19(9):427-34.

9. 9. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human infl ammatory bowel diseases. Proc Natl Acad Sci U S A. 2007;21;104(34):13780-5.
10. 10. Eckburg PB, Relman DA. The role of microbes in Crohn's disease. Clin Infect Dis. 2007; 15;44(2):256-62.
11. 11. Schulberg J, De Cruz P. Characterisation and therapeutic manipulation of the gut microbiome in infl ammatory bowel disease. Intern Med J 2016;46:266-73.
12. 12. Gagnière J, Raisch J, Veziant J, et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol 2016;22:501-18.
13. 13. Winer DA, Luck H, Tsai S, et al. The Intestinal Immune System in Obesity and Insulin Resistance. Cell Metab 2016;23:413-26.
14. 14. Xuan C, Shamonki JM, Chung A, et al. Microbial dysbiosis is associated with human breast cancer. PLoS One 2014;9:e83744.
15. 15. Cryan JF, O’Mahony SM. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil 2011;23:187-92.
16. 16. Diaz Heijtz R, Wang S, Anuar F, et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci 2011;108:3047-52.
17. 17. Hooton TM, Stamm WE. The vaginal fl ora and urinary tract infections. In:Warren JW, Mobley HL, editors. Urinary tract infections: molecular pathogenesis and clinical management. Washington, DC: ASM Press; 1996. p. 67.
18. 18. Pfau A, Sacks T. The bacterial fl ora of the vaginal vestibule, urethra and vagina in premenopausal women with recurrent urinary tract infections. J Urol 1981;126(5):630–4.
19. 19. Atassi F, Servin AL. Individual and co-operative roles of lactic acid and hydrogen peroxide in the killing activity of enteric strain Lactobacillus johnsonii NCC933 and vaginal strain Lactobacillus gasseri KS120.1 against enteric, uropathogenic and vaginosisassociated pathogens. FEMS Microbiol Lett. 2010;304(1):29-38.
20. 20. Donders GG, Vereecken A, Bosmans E, Spitz B. Vaginal cytokines in normal pregnancy. Am J Obstet Gynecol. 2003;189(5):1433-8.
21. 21. Spurbeck RR, Arvidson CG Inhibition of Neisseria gonorrhoeae epithelial cell interactions by vaginal Lactobacillus species. Infect Immun 2008;76:3124–3130.
22. 22. Hooton TM, Scholes D, Gupta K, et al. Amoxicillin-clavulanate vs ciprofl oxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA 2005;293(8):949-55.
23. 23. Hooton TM, Roberts PL, Stapleton AE. Cefpodoxime vs ciprofl oxacin for shortcourse treatment of acute uncomplicated cystitis: a randomized trial. JAMA 2012;307(6):583–9.
24. 24. Raz R. Urinary tract infection in postmenopausal women. Korean J Urol 2011; 52(12):801–8.
25. 25. HootonTM, Fihn SD, JohnsonC, et al. Association between bacterial vaginosis and acute cystitis in women using diaphragms. Arch Intern Med 1989;149(9):1932–6.
26. 26. Schwebke JR. Abnormal vaginal fl ora as a biological risk factor for acquisition of HIV infection and sexually transmitted diseases. J Infect Dis.2005;15;192(8):1315-7.
27. 27. Nelson DE, Dong Q, Van der Pol B, Toh E, Fan B, Katz BP, Mi D, Rong R,Weinstock GM, Sodergren E, Fortenberry JD. Bacterial communities of the coronal sulcus and distal urethra of adolescent males. PLoS One. 2012;7(5):e36298.
28. 28. David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014;505:559-63
29. 29. Wilcox MH. Gastrointestinal disorders and the critically ill. Clostridium diffi cile infection and pseudomembranous colitis. Best Pract Res Clin Gastroenterol 2003;17:475-93.
30. 30. Beaugerie L, Petit JC. Microbial-gut interactions in health and disease. Antibiotic-associated diarrhoea. Best Pract Res Clin Gastroenterol 2004;18:337-52.
31. 31. D.S. Goldfarb, M.E. Fischer, Y. Keich, et al., A twin study of genetic and dietary infl uences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry, Kidney Int.2005;67:1053.
32. 32. Adel-Patient K, Ah-Leung S, Creminon C, Nouaille S, Chatel JM, Langella P & Wal JM Oral administration of recombinant Lactococcus lactis expressing bovine betalactoglobulin partially prevents mice from sensitization. Clin Exp Allergy 2005;35:539- 546.
33. 33. Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J & Hultgren SJ Intracellular bacterial biofi lm-like pods in urinary tract infections. Science 2003;301:105-107.
34. 34. Beigi RH, Wiesenfeld HC, Hillier SL, Straw T & Krohn MA Factors associated with absence of H2O2-producing Lactobacillus among women with bacterial vaginosis. J Infect Dis 2005;191:924-29.
35. 35. Cadieux P, Burton J, Gardiner G, Braunstein I, Bruce AW, Kang CY & Reid G Lactobacillus strains and vaginal ecology. JAMA 2002;287:1940-41.
36. 36. Dendukuri N, Costa V, McGregor M & Brophy JM (2005) Probiotic therapy for the prevention and treatment of Clostridium diffi cileassociated diarrhea: a systematic review. CMAJ 2005;173:167-70.
37. 37. Elliot E & Teversham K An evaluation of nine probiotics available in South Africa, S Afr Med J 2003;94:121-24.
38. 38. Gan BS, Kim J, Reid G, Cadieux P & Howard JC Lactobacillus fermentum RC-14 inhibits Staphylococcus aureus infection of surgical implants in rats. J Infect Dis 2002;185: 1369-72.
39. 39. Gill HS, Rutherfurd KJ, Cross ML & Gopal PK Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifi dobacterium lactis HN019. Am J Clin Nutr 2001;74:833-39.
40. 40. Grozdanov L, Raasch C, Schulze J, Sonnenborn U, Gottschalk G,Hacker J & Dobrindt U Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. J Bacteriol 2004;186:5432–5441.
41. 41. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C & Sartor RBVSL#3 Probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100:1539-46.
42. 42. Roberts RO, Lieber MM, Rhodes T, et al. Prevalence of a physicianassigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology 1998;51:578-84.
43. 43. Taylor BC, Noorbaloochi S, McNaughton-Collins M, et al. Excessive antibiotic use in men with prostatitis. Am J Med 2008;121:444-9.
44. 44. Nickel JC. Treatment of chronic prostatitis/chronic pelvic pain syndrome. Int J Antimicrob Agents 2008;31 Suppl 1:S112-16.
45. 45. Shoskes DA. Use of the biofl avonoid quercetin in patients with longstanding chronic prostatitis. J Am Neutraceutical Assoc 1999;2:18-21.
46. 46. Etxeberria U, Arias N, Boqué N, et al. Reshaping faecal gut microbiota composition by the intake of trans-resveratrol and quercetin in high-fat sucrose diet-fed rats. J Nutr Biochem 2015;26:651-60.
47. 47. Ivanov IB, Kuzmin MD, Gritsenko VA. Microfl ora of the seminal fl uid of healthy men and men suffering from chronic prostatitis syndrome. Int J Androl. 2009t;32(5):462-7.
48. 48. Palapattu GS, Sutcliffe S, Bastian PJ, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005; 26:1170-81.
49. 49. Yu H, Meng H, Zhou F, Ni X, Shen S, Das UN. Urinary microbiota in patients with prostate cancer and benign prostatic hyperplasia. Arch Med Sci. 2015;25;11(2):385-94.
50. 50. Spandorfer SD, Neuer A, Giraldo PC, Rosenwaks Z, Witkin SS. Relationship of abnormal vaginal fl ora, proinfl ammatory cytokines and idiopathic infertility in women undergoing IVF. J Reprod Med 2001;46:806e10.
51. 51. Ugwumadu A. Role of antibiotic therapy for bacterial vaginosis and intermediate fl ora in pregnancy. Best Pract Res Clin Obstet Gynaecol 2007;21:391e402.
52. 52. Dohle GR. Infl ammatory-associated obstructions of the male reproductive tract. Andrologia 2003;35:321e4.
53. 53. Erenpreiss J, Spano M, Erenpreisa J, Bungum M, Giwercman A. Sperm chromatin structure and male fertility: biological and clinical aspects. Asian J Androl 2006;8:11e29.
54. 54. Mändar R, Raukas E, Türk S, Korrovits P, Punab M. Mycoplasmas in semen of chronic prostatitis patients. Scand J Urol Nephrol 2005;39:479e82.
55. 55. Borovkova N, Korrovits P, Ausmees K, Türk S, Jõers K, Punab M, Mändar R. Infl uence of sexual intercourse on genital tract microbiota in infertile couples. Anaerobe. 2011;17(6):414-18.
56. 56. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, Kiwanuka N, Moulton LH, Chaudhary MA, Chen MZ, Sewankambo NK, Wabwire-Mangen F, Bacon MC, Williams CF, Opendi P, Reynolds SJ, Laeyendecker O, Quinn TC, Wawer MJ. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007;369:657-66.
57. 57. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CF, Campbell RT, Ndinya-Achola JO. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007;369:643-56.
58. 58. Tobian AA, Serwadda D, Quinn TC, Kigozi G, Gravitt PE, Laeyendecker O, Charvat B, Ssempijja V, Riedesel M, Oliver AE, Nowak RG, Moulton LH, Chen MZ, Reynolds SJ, Wawer MJ, Gray RH. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N. Engl. J. Med. 2009;360:1298-1309.
59. 59. Sobngwi-Tambekou J, Taljaard D, Nieuwoudt M, Lissouba P, Puren A, Auvert B. Male circumcision and Neisseria gonorrhoeae, Chlamydia trachomatis and Trichomonas vaginalis: observations after a randomised controlled trial for HIV prevention. Sex. Transm. Infect. 2009;85:116-20.
60. 60. Mehta SD, Moses S, Agot K, Parker C, Ndinya-Achola JO, Maclean I, Bailey RC. Adult male circumcision does not reduce the risk of incident Neisseria gonorrhoeae, Chlamydia trachomatis, or Trichomonas vaginalis infection: results from a randomized, controlled trial in Kenya. J. Infect. Dis.2009;200:370-78.
61. 61. Price LB, Liu CM, Johnson KE, Aziz M, Lau MK, Bowers J, Ravel J, Keim PS,Serwadda D, Wawer MJ, Gray RH. The effects of circumcision on the penis microbiome. PLoS One. 2010; 6;5(1):e8422.
62. 62. Gunsar C, Kurutepe S, Alparslan O, Yilmaz O, Daglar Z, Sencan A, et al. The effect of circumcision status on periurethral and glanular bacterial fl ora. Urol Int 2004;72:212-5.
63. 63. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: The ANRS 1265 Trial. PLoS Med 2005;2:e298.
64. 64. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: A randomised controlled trial. Lancet 2007;369:643-56.
65. 65. Gray RH, Kigozi G, Serwadda D, Makumbi F, Nalugoda F, et al. (2009) The effects of male circumcision on female partners’ genital tract symptoms and vaginal infections in a randomized trial in rakai, uganda. Am J Obstet Gynecol 200(1):42.e1-42.e7.
66. 66. de Jong MA, Geijtenbeek TB. Human immunodefi ciency virus-1 acquisition in genital mucosa: Langerhans cells as key-players. J Intern Med 2009;265(1):18-28.
67. 67. Hoesl, C. E. & Altwein, J. E. The probiotic approach: an alternative treatment option in urology. Eur. Urol. 2005;47: 288–296
68. 68. Fahmy, N., Lazo-Langner, A., Iansavichene, A. E. & Pautler, S. E. Effect of anticoagulants and antiplatelet agents on the effi cacy of intravesical BCG treatment of bladder cancer: a systematic review. Can. Urol. Assoc. J. 2013;7:E740–E749.
69. 69. Kuroda, K., Brown, E. J., Telle, W. B., Russell, D. G. & Ratliff, T. L. Characterization of the bacillus Calmette-Guérin by human bladder tumor cells. J. Clin. Invest.1993;91:69-76.
70. 70. Aso, Y. & Akazan, H. Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superfi cial bladder cancer. BLP Study Group. Urol. Int. 1992;49:125-29.
71. 71. Power SE, O’Toole PW, Stanton C et al. Intestinal microbiota, diet and health. Br J Nutr 2014;111:387-402.
72. 72. Vaziri ND, Wong J, Pahl M et al. Chronic kidney disease alters intestinal microbial fl ora. Kidney Int 2012; 83: 308–315.
73. 73. Satoh, M. et al. Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure. Nephron Exp. Nephrol. 2003;95:e111-e118.
74. 74. Evenepoel, P., Meijers, B. K., Bammens, B. R. & Verbeke, K. Uremic toxins originating from colonic microbial metabolism. Kidney Int. Suppl. 2009;76: S12–S19.
75. 75. Vaziri ND, Zhao Y-Y, Pahl MV. Altered intestinal microbial fl ora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrol Dial Transplant 2015 (doi:10.1093/ndt/gfv095).
76. 76. Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol 2008;8:411-20.
77. 77. Keddis MT, Khanna S, Noheria A et al. Clostridium diffi cile infection in patients with chronic kidney disease. Mayo Clin Proc 2012;87:1046-53.
78. 78. Croxall G et al.: Increased human pathogenic potential of Escherichia coli from polymicrobial urinary tract infections in comparison to isolates from monomicrobial culture samples. J Med Microbiol 2011;60(Pt 1):102-109.
79. 79. Kline KA et al. Impact of host age and parity on susceptibility to severe urinary tract infection in a murine model. PLoS ONE 2014;9:e97798.
80. 80. Dethlefsen L, Huse S, Sogin ML, et al. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008;6:e280.
81. 81. Rahn DD. Urinary tract infections: contemporary management. Urol Nurs2008; 28(5):333-41.
82. 82. Samra KSS, Cenk S, Horu GMG, Beril O. Increasing antimicrobial resistance of Escherichia coli isolates from community acquired UTI during 1998-2003. Manisa Turkey Japan. J Infect Dis 2005;58:159- 61.
83. 83. Borchert D, Sheridan L, Papatsoris A, Faruqu Z, Barua JM, Junaid I et al. Prevention and treatment of urinary tract infection with probiotics: review and research perspective. Indian J Urol 2008;24:139-44.
84. 84. Smith RD, Yago M, Millar M, Coast J. A macroeconomic approach to evaluating policies to contain antimicrobial resistance: a case study of methicillin resistant Staphylococcus aureus (MRSA). Appl Health Econ Health Pol 2006;5:55-65.
85. 85. Kaewnopparat S, Kaewnopparat N. Formulation and evaluation of vaginal suppositories containing Lactobacillus. World Acad Sci Eng Technol 2009;55:640-43.
86. 86. Bruce AW, Reid G. Probiotics and the urologist. Can J Urol 2003;270(7230):16-18.
87. 87. Reid G, Chan RCY, Bruce AW, Costerton JW. Prevention of urinary tract infection in rats with indigenous Lactobacillus casei strain. Infect Immun 1985;49(2):320-24.
88. 88. Yılmaz Mustafa. Prebiyotik ve Probiyotikler. Güncel Pediatri 2004;2:142-45
89. 89. Isolauri E, Kirjavainen PV, Salminen S. Probiotics role in the treatment of intestinal infection and infl ammation? Gut 2002;50(suppl IIP):54–9.
90. 90. Szajewska H, Mrukowich JZ. Probiotics in the teatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo controlled trial. J Pediatr Gastroenterol Nutr 2001;33:17-25.
91. 91. Dugas B, Mercenier A, Lenoir-Winjkoop I, et al. Immunity and probiotics. Immunol Today 1999;20:387-90.
92. 92. Stapleton, A. E. et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin. Infect. Dis. 2011;52:1212-17.
93. 93. Bjorksten B, Naaber P, Sepp E, et al. The intestinal microfl ora in allergic Estonian and Swedish 2-year old children. Clin Exp Allergy 1999;29:342-6.
94. 94. Isolauri, E., Joensuu, J., Suomalainen, H., Luomala, M., & Vesikari, T. Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine 1995;13:310-12.
95. 95. Duncan, S. H. et al. Oxalobacter formigenes and its potential role in human health. Appl. Environ. Microbiol. 2002;68:3841-47.
96. 96. Campieri, C. et al. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int. 2001;60:1097- 1105.
97. 97. Youngster, I. et al. Fecal microbiota transplant for relapsing Clostridium diffi cile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin. Infect. Dis. 2014;58:1515-22.
98. 98. Vrieze, A. et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012;143:913-16.e7.
99. 99. Arora HC, Eng C, Shoskes DA. Gut microbiome and chronic prostatitis/chronic pelvic pain syndrome. Ann Transl Med. 2017;5(2):30.